RPG LIFE SCIENCES LTD. SHARE PRICE [LIVE]

  
NSE: RPGLIFE
867.05
BSE: 532983
865.70
To view real time prices Login to your account
OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality

Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
41.01%
Sector
-6.89%
Sensex
9.67%
Outperformed both Sector by 47.9% and Sensex by 31.34%
IndustryPharma
MARKET CAP (Micro Cap Stock)Rs 1,450 Cr
PE (TTM) 23.95
DIVIDEND YIELD 1.10%
PE Ratio23.95
Price to Book Value5.65
EV to EBIT17.24
EV to EBITDA14.45
EV to Capital Employed7.38
EV to Sales2.85
PEG Ratio1.05
Dividend Yield1.10%
ROCE (Latest)37.92%
ROE (Latest)23.59%
NameSep 22Jun 22
Promoters (Change:0.20) 72.61%72.41%
FIIs (Change:-0.07) 0.08%0.15%
Mutual Funds (Change:0.00) 0%0%
Insurance Companies (Change:0.00) 0%0%
Other DIIs (Change:2.03) 2.04%0.01%
Non Institution (Change:-2.16) 25.27%27.43%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in RPG LIFE SCIENCES LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

RPGLIFE News

Frequently Asked Questions

What is the Share price of RPG LIFE SCIENCES LTD. (RPGLIFE)?

RPG LIFE SCIENCES LTD. (RPGLIFE) share price as of November 29, 2022, on NSE is Rs 867.05 (NSE) and Rs 865.70 (BSE) on BSE.

Can I buy RPG LIFE SCIENCES LTD. (RPGLIFE) shares?

Yes, You can buy RPG LIFE SCIENCES LTD. (RPGLIFE) shares by opening a Demat account with Angel One.

How do I buy RPG LIFE SCIENCES LTD. (RPGLIFE) from Angel One?

RPG LIFE SCIENCES LTD. (RPGLIFE) share can be brought through the following modes:
  1. Direct investment: You can buy RPG LIFE SCIENCES LTD. (RPGLIFE) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to RPG LIFE SCIENCES LTD. (RPGLIFE) shares.

In which sector do RPG LIFE SCIENCES LTD. (RPGLIFE) belong?

RPG LIFE SCIENCES LTD. (RPGLIFE) belongs to Pharma.

About RPGLIFE

Today's live share price for RPG LIFE SCIENCES LTD. is NSE: ₹ 867.05, BSE: ₹ 865.70 with a current market capitalization of .

RPG Life Sciences Ltd is engaged in the development, manufacture, and marketing of bulk drugs and formulations primarily in India. The company provides active pharmaceutical ingredients and generic formulations, as well as medications for critical and chronic ailments. They also manufacture life saving drugs using biotechnology. The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers